Analysts Issue Research Notes On Minerva Surgical Inc. (UTRS)

0
14

Minerva Surgical Inc. (NASDAQ:UTRS) finished Wednesday with an addition of $0.16 to close at $0.38, an upside of 72.37 percent. An average of 4,277,920 shares of common stock have been traded in the last five days. There was a gain of $0.1550 in the past week, and it reached a new high 11 times over the past 12 months. The last 20 days have seen an average of 2,970,210 shares traded, while the 50-day average volume stands at 1,365,320.

UTRS stock has increased by 117.09% in the last month. The company shares reached their 1-month lowest point of $0.1499 on 12/27/22. With the stock rallying to its 52-week high on 01/25/23, shares of the company touched a low of $0.15 and a high of $6.04 in 52 weeks. It has reached a new high 3 times so far this year and achieved 70.05% or $0.1565 in price. In spite of this, the price is down -93.71% from the 52-week high.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Valuation Metrics

Minerva Surgical Inc. (UTRS) has a trailing price-to-sales (P/S) ratio at 0.23, the price-to-book (PB) ratio at 0.51.

Financial Health

The quick ratio of Minerva Surgical Inc. for the three months ended September 29 was 1.40, and the current ratio was 2.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.83 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $30.52 million compared to revenue of $52.1 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Minerva Surgical Inc.’s return on assets was -17.30%.

Earnings Surprise

For the three-month period that ended September 29, Minerva Surgical Inc. had $39.27 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$11.33 million in the quarter, while revenues of -$5.61 million were grew 71.49%. The analyst consensus anticipated Minerva Surgical Inc.’s latest quarter earnings to come in at -$0.28 per share, but it turned out to be -$0.4, a -42.90% surprise. For the quarter, EBITDA amounted to -$7.75 million. Shareholders own equity worth $28.97 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Minerva Surgical Inc. (UTRS) price momentum. RSI 9-day as of the close on 25 January was 82.32%, suggesting the stock is Overbought, with historical volatility in this time frame at 279.44%.

As of today, UTRS’s price is $0.2501 +68.92% or $0.1550 from its 5-day moving average. UTRS is currently trading +136.99% higher than its 20-day SMA and -77.65% lower than its 100-day SMA. However, the stock’s current price level is +21.18% above the SMA50 and -91.50% below the SMA200.

The stochastic %K and %D were 36.72% and 28.50%, respectively, and the average true range (ATR) was 0.0723. With the 14-day stochastic at 45.47% and the average true range at 0.0606, the RSI (14) stands at 74.44%. The stock has reached 0.0305 on the 9-day MACD Oscillator while the 14-day reading was at 0.0375.

Analyst Ratings

UBS launched coverage on Minerva Surgical Inc. (NASDAQ: UTRS) in its analyst report released on November 16, 2021. The firm assigned the stock a Buy rating. The consensus rating for Minerva Surgical Inc. (UTRS) among analysts is Sell. According to current brokerage recommendations, 1 brokerage firm advise that investors sell UTRS, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.

What is UTRS’s price target for the next 12 months?

Analysts predict a range of price targets between $5.00 and $5.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for Minerva Surgical Inc. (UTRS) stock is $5.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here